The British Institute of Radiology Welcomes
21 May 2014
The British Institute of Radiology welcomes
Guerbetas new corporate subscriber
Guerbet have joined the BIR as a corporate subscriber.Guerbet produces contrastagents and offers medical devices and injectors from partner companies for use in the medical imaging market.
The BIR now has 23 corporate subscribers who benefit from membership of the BIR.
BIR corporate subscribers are encouraged to join BIR special interest groups, to collaborate in developing educational events and to get involved with publishing activities.
Jacqueline Fowler, Chief Executive of the BIR said, “It is a pleasure to have Guerbet on board as a corporate subscriber. We welcome their involvement and look forward to seeing Guerbet not only at our events but getting involved with our special interest groups.”
Levi Cheng, General Manager at Guerbet, said, “Being a corporate subscriber and an integral part of the BIR community means that we can interact and meet all disciplines in the medical imaging world. We are very much looking forward to working together.”
Guerbet joins corporate subscribers Agfa Healthcare UK, Alliance Medical Ltd, Bayer Healthcare, Bracco UK Ltd, Canon (UK) Ltd, Carestream Health, Cobalt Appeal Fund, Envirotect Ltd, Esaote UK, Fujifilm, GE Medical Systems Ltd, Imaging Equipment Ltd, Insignia Medical Systems, Leeds Test Objects/Mediscientific, Mallinckrodt (UK) Commercial Ltd, Medica Reporting Ltd, Philips Healthcare, Sectra Ltd, Siemens Healthcare, Toshiba Medical Systems Ltd and Wardray Premise Ltd.
Ends
Photo attached.
Caption: General Manager Levi Cheng with BIR Chief Executive, Jacqueline Fowler
Notes to Editors
About The British Institute of Radiology
- The British Institute of Radiology (BIR) is an independent multidisciplinary organisation, and a registered charity, whose membership is open to everyone with an interest in radiology and radiation oncology.
- The British Institute of Radiology is the oldest radiological society in the world.
- We strive to ensure that the potential of image science and radiation technology to prevent, detect and combat disease is fully realised. We believe in the importance of research and education, and we promote collaboration and the sharing of knowledge and understanding.
- To help fulfil our aims, we undertake a wide range of activities, including publishing, the organisation of scientific meetings and conferences and the provision of library and information services.
About Guerbet
Since 1926, theGuerbet Grouphas had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Paris, France, Guerbet is a publicly traded company holding more than 25% of the European market share and 7% of the worldwide contrast media market.
Guerbet makes full use of its know-how and innovative capacity to meet the major public health challenges of the 21st century.
Guerbet works in the diagnosis of majordisease areas (cancer, cardiovascular, inflammatory and neurodegenerative diseases).
For information about this release please contact:
Carole Cross
Communications Manager
48-50 St John Street
London EC1M 4DG
Tel. 020 3668 2224